Pathogenesis and glycemic management of type 2 diabetes mellitus: A physiological approach

Archives of Iranian Medicine

Volumn 15, Issue 4, 2012, Pages 239-246

  Ismail Beigi, Faramarz ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

cell number; Disposition index; Glycemic target range; Insulin resistance

Indexed keywords

ACARBOSE; BROMOCRIPTINE; COLESEVELAM; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; LONG ACTING INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; PROTEIN INHIBITOR; REPAGLINIDE; SAXAGLIPTIN; SHORT ACTING INSULIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ATHEROSCLEROSIS; B LYMPHOCYTE; BARIATRIC SURGERY; BEDTIME DOSAGE; BLADDER CANCER; BLINDNESS; CARDIOVASCULAR DISEASE; CELL FUNCTION; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIET; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE TITRATION; EDEMA; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; LEG AMPUTATION; LIFESTYLE MODIFICATION; MORTALITY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIDE EFFECT; SOCIOECONOMICS; WEIGHT GAIN; METABOLISM;

DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE;

EID: 84862267597     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Hardoon SL, Morris RW, Thomas MC, Wannamethee SG, Lennon LT, Whincup PH. Is the recent rise in type 2 diabetes incidence from 1984 to 2007 explained by the trend in increasing BMI? Diabetes Care. 2010; 33:1494-1496.
2. Narayan KMV, Ali MK, Koplan JP. Global noncommunicable disease where world meet. NEngl J Med. 2010; 363: 1196-1198.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229-234.
4. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375: 2215-2222.
5. Beaglehole R, Bonita R, Alleyne G, Horton R, Li L, Lincoln P, et al. Lancet NCD Action Group. UN High-Level Meeting on Non-Communicable Diseases: Addressing four questions. Lancet. 2011; 378: 449-455.
6. DeFronzo R. From the triumvirate to the ominous octet: a new paradigm for the treatment of type diabetes mellitus. Diabetes. 2009; 58: 773-795.
7. Boden G, Chen X, Stein TP. Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus. Am J Physiol. 2001; 280: E23-E30.
8. Færch K, Vaag A, Holst JJ, Hansen T, Jorgensen, T, Borch-Johnson K. Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glyce-mia and impaired glucose tolerance: the Inter99 Study. Diabetes Care. 2009; 32: 439-444.
9. Lorenzo C, Wagenknecht L, D'Agostino R, Rewers M, Karter A, Haffner S. Insulin resistance, β-cell dysfunction, and conversion to type 2 diabetes in a multiethnic population. Diabetes Care. 2010; 33: 67-72.
10. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection, and clinical use. Am J Med. 2009; 122: S37-S50.
11. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003; 52: 102-110.
12. Rahier J, Guiot Y, Goebbels RM, Sempiux C, Henquin JC. Pancreatic β-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 10 (suppl 4): 32-42.
13. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999; 104: 787-794.
14. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995; 44: 1249-1258.
15. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 2001; 44: 929-945.
16. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet. 2008; 40: 638-645.
17. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010; 42: 579-589.
18. American Diabetes Association. Standards of Medical Care in Diabetes-2011. Diabetes Care. 2011; 34: S11-S61.
19. C for the diagnosis of diabetes. EndocrPract. 2010; 16: 155-156.
20. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986.
21. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEngl J Med. 2005; 353: 2643-2653.
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
23. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995; 28: 103-117.
24. Duckworth WC, Abraira C, Moritz TE, Reda DJ, Emauele N, Reaven PD, et al. Glucose control and vascular complications in veterans with. type 2 diabetes. NEngl J Med. 2009; 360: 129-139.
25. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572.
26. The ACCORD Study Group, The ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363: 233-244.
27. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. The ACCORD Study Group. Effect of intensive treatment of 51. hyperglycemia on microvascular complications of type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet. 2010; 376: 419-430.
28. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. The ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559.
29. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009; 52: 2288-2298.
30. Holman RR, Paul SK, Bethel M, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-1589.
31. Gaede P, Lund-Anderson H, Parving HH, Pedersen O. Effect of multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580-589.
32. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, et al. Look AHEAD Research Group. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: Results from the Look AHEAD trial. Diabetes Care. 2011; 34: 2152-2157.
33. American Association of Clinical Endocrinologists Board of Directors, American College of Endocrinologists Board of Trustees. Statement by an AACE/ACE consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009; 15: 540-559.
34. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: Implications of recent clinical trials. Ann Intern Med. 2011; 154: 554-559.
35. Mezuk B, Eaton WW, Albrecgt S, Golden SH. Depression and type 2 diabetes over the lifespan: a metaanalysis. Diabetes Care. 2008; 31: 2383-2390.
36. Bonds DE, Miller ME, Bergenstal R, Buse JB, Byington RP, Cutler J, et al. The relationship between severe hypoglycemia and mortality in type 2 diabetes: The ACCORD Study. BMJ. Epub 2010.
37. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009; 301: 1565-1572.
38. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003; 26: 1485-1489.
39. The ADVANCE Collaborative Group. Severe hypoglycemia and risk of vascular events and death. NEngl J Med. 2010; 363: 1410-1418.
40. Nathan DA, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. The ADAG Group. Translating the A1c assay into estimated average glucose values. Diabetes Care. 2008; 31: 1473-1478.
41. Wolfram T, Ismail-Beigi F. Efficacy of diets containing high amounts of fiber in the management of type 2 diabetes. Endocr Practice. 2011; 17:132-142.
42. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403.
43. Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program. Diabetes. 2005; 54: 2404-2414.
44. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The longterm effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet. 2008; 371:1783-1789.
45. Ralston JD, Hirsch IB, Hoath J, Mullen M, Cheadle A, Goldberg HI. Web-based collaborative care for type 2 diabetes: a pilot randomized trial. Diabetes Care. 2009; 32: 234-239.
46. Wennberg DE, Marr A, Lang L, O'Malley S, Bennett G. A randomized trial of a telephone care-management strategy. N Engl J Med. 2010;363:1245-1255.
47. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001; 24: 758-767.
48. Bolen S, Feldman L, Vassy J, Wilson L, Yeh H-C, Marinopoulos S, et al. Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007; 147: 386-399.
49. Kahn S, Haffner S, Heise M, Herman W, Holman R, Jones N, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355: 2427-2443.
50. Nathan DM. Finding new treatments for diabetes-how many, how fast...how good? N Engl J Med. 2007; 356: 437-440.
51. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones, MR. Cole-sevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008; 31: 1479-1484.
52. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009; 361: 1736-1747.
53. Nathan DM, Buse JB, Davidson MB, Holman RR, Sherwin R, Zin-man B. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203.
54. Gaziano JM, Cincotta AH, O'Connor CM, Ezrokhi M, Rutty D, Ma ZJ, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010; 33: 1503-1508.
55. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007; 298:194-206.
56. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications. Am J Med. 2011; 124: S3-S18.
57. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011; 13: 7-18.
58. Duez H, Cariou B, Staels B. DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol. 2012; 83: 23-32.
59. Gross JL, Kramer CK, Leitao CB, Hawkins N, Viana LV, Schaan BD, et al. Diabetes and Endocrinology Meta-analysis Group (DEMA). Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011; 154: 672-679.
60. Loke YK, Kwok CS, Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ. 2011; 342: d1309.
61. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011; 154: 103-112.
62. Bergenstal R, Bailey CJ, Kendall DM. Type 2 diabetes: Assessing relative risks and benefits of glucose-lowering medications. Am J Med. 2010; 123: 374. e9-e18.
63. Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism. 2011; 60: 1-23.
64. DeFronzo RA. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med. 2010; 123: S38-S48.
65. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations. Ann Intern Med. 2011; 154: 602-613.
66. Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P. A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract. 2011; 17: 395-403.
67. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med. 1999; 30: 389-396.
68. Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting β-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010; 95: 4206-4216.
69. Nyalakonda K, Sharma T, Ismail-Beigi F. Preservation of beta cell function in type 2 diabetes. Endocr Practice. 2010: 16: 1038-1055.
70. Sjostrom L, Lindroos AK, Peitonene M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Eng J Med 2004; 351: 2683-2693.
71. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009; 122: 248-256.